A Method for Accurately Assessing the Latent Virus Reservoir in Chronic HIV Patients
|
By LabMedica International staff writers Posted on 20 Apr 2021 |

Image: HIV assembling on the surface of an infected macrophage. The HIV virions have been marked with a green fluorescent tag and then viewed under a fluorescent microscope (Photo courtesy of Wikimedia Commons)
A modified version of the PCR test can determine the quantity and quality of inactive human immunodeficiency virus (HIV) in the genes of individuals suffering from chronic HIV.
While HIV is not curable, antiretroviral therapy drugs (ARTs) effectively suppress the HIV virus to undetectable levels. Nonetheless, a latent HIV reservoir persists due to HIV's integration into the host DNA, specifically in the chromosomes of T lymphocytes and macrophages. Quantifying this replication-competent HIV reservoir is essential for evaluating prognostic and curative strategies.
Currently used viral outgrowth assays (VOAs) underestimate the reservoir because they fail to induce all replication-competent proviruses. Single- or double-region HIV DNA assays overestimate it because they fail to exclude many defective proviruses.
To correct for the over and under estimation of the latent HIV reservoir, investigators at the University of Washington (Seattle, USA) designed two triplex droplet digital PCR (ddPCR) assays, each with two unique targets and one in common, and normalized the results to PCR-based T-cell counts.
The classical PCR test carries out one reaction per single sample. The digital PCR (dPCR) method also carries out a single reaction within a sample, however the sample is separated into a large number of partitions and the reaction is carried out in each partition individually. This separation allows a more reliable collection and sensitive measurement of nucleic acid amounts. The dPCR method has been demonstrated as useful for studying variations in gene sequences - such as copy number variants and point mutations - and it is routinely used for clonal amplification of samples for next-generation sequencing.
Droplet digital PCR (ddPCR) is a variation of dPCR in which a 20 microliter sample reaction including assay primers and either Taqman probes or an intercalating dye, is divided into about 20,000 nanoliter-sized oil droplets through a water-oil emulsion technique, thermocycled to endpoint in a 96-well PCR plate, and fluorescence amplitude read for all droplets in each sample well in a droplet flow cytometer.
A ddPCR assay protocol reported in 2019 probed two regions of the HIV-1 genome within each droplet. For the current study, the investigators used two three-region (triplex) ddPCR assays to develop a five-region test (one overlapping region allowed inter-assay quality control). They referred to triple-positive ddPCR droplets as “potentially intact.” By combining the two parallel triplex assays, they could confidently quantify truly intact HIV-1 viral genomes. As a further enhancement, they adapted a multiplexed ddPCR assay specifically quantifying T-cells to accurately normalize to the number of HIV target cells interrogated. This additional step was especially useful for tissue biopsies, because, in contrast to blood, cell populations in tissues were difficult to isolate and purify.
Results obtained during this study revealed that both HIV ddPCR assays were specific, sensitive, and reproducible. Together, they estimated the number of proviruses containing all five primer-probe regions. The five-target results were on average 12.1-fold higher than and correlated with paired quantitative VOA but estimated a markedly smaller reservoir than previous DNA assays.
"Our laboratory test is a simpler way to quantify the reservoir of intact viruses," said senior author Dr. Florian Hladik, research professor of obstetrics and gynecology at the University of Washington. "I can see a patient going to a doctor and adding this to the list of questions they might ask. Now they ask about their viral load and T-cell count. I hope in the future they may be able to ask how large their HIV reservoir might be. What gets me excited is that one day, this number may tell them how long it will take to entirely eliminate HIV from their body."
The study was published in the April 12, 2021, online edition of the journal Cell Reports Medicine.
Related Links:
University of Washington
While HIV is not curable, antiretroviral therapy drugs (ARTs) effectively suppress the HIV virus to undetectable levels. Nonetheless, a latent HIV reservoir persists due to HIV's integration into the host DNA, specifically in the chromosomes of T lymphocytes and macrophages. Quantifying this replication-competent HIV reservoir is essential for evaluating prognostic and curative strategies.
Currently used viral outgrowth assays (VOAs) underestimate the reservoir because they fail to induce all replication-competent proviruses. Single- or double-region HIV DNA assays overestimate it because they fail to exclude many defective proviruses.
To correct for the over and under estimation of the latent HIV reservoir, investigators at the University of Washington (Seattle, USA) designed two triplex droplet digital PCR (ddPCR) assays, each with two unique targets and one in common, and normalized the results to PCR-based T-cell counts.
The classical PCR test carries out one reaction per single sample. The digital PCR (dPCR) method also carries out a single reaction within a sample, however the sample is separated into a large number of partitions and the reaction is carried out in each partition individually. This separation allows a more reliable collection and sensitive measurement of nucleic acid amounts. The dPCR method has been demonstrated as useful for studying variations in gene sequences - such as copy number variants and point mutations - and it is routinely used for clonal amplification of samples for next-generation sequencing.
Droplet digital PCR (ddPCR) is a variation of dPCR in which a 20 microliter sample reaction including assay primers and either Taqman probes or an intercalating dye, is divided into about 20,000 nanoliter-sized oil droplets through a water-oil emulsion technique, thermocycled to endpoint in a 96-well PCR plate, and fluorescence amplitude read for all droplets in each sample well in a droplet flow cytometer.
A ddPCR assay protocol reported in 2019 probed two regions of the HIV-1 genome within each droplet. For the current study, the investigators used two three-region (triplex) ddPCR assays to develop a five-region test (one overlapping region allowed inter-assay quality control). They referred to triple-positive ddPCR droplets as “potentially intact.” By combining the two parallel triplex assays, they could confidently quantify truly intact HIV-1 viral genomes. As a further enhancement, they adapted a multiplexed ddPCR assay specifically quantifying T-cells to accurately normalize to the number of HIV target cells interrogated. This additional step was especially useful for tissue biopsies, because, in contrast to blood, cell populations in tissues were difficult to isolate and purify.
Results obtained during this study revealed that both HIV ddPCR assays were specific, sensitive, and reproducible. Together, they estimated the number of proviruses containing all five primer-probe regions. The five-target results were on average 12.1-fold higher than and correlated with paired quantitative VOA but estimated a markedly smaller reservoir than previous DNA assays.
"Our laboratory test is a simpler way to quantify the reservoir of intact viruses," said senior author Dr. Florian Hladik, research professor of obstetrics and gynecology at the University of Washington. "I can see a patient going to a doctor and adding this to the list of questions they might ask. Now they ask about their viral load and T-cell count. I hope in the future they may be able to ask how large their HIV reservoir might be. What gets me excited is that one day, this number may tell them how long it will take to entirely eliminate HIV from their body."
The study was published in the April 12, 2021, online edition of the journal Cell Reports Medicine.
Related Links:
University of Washington
Latest Molecular Diagnostics News
- Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test
- Blood Test Detects Early-Stage Cancers by Measuring Epigenetic Instability
- Two-in-One DNA Analysis Improves Diagnostic Accuracy While Saving Time and Costs
- “Lab-On-A-Disc” Device Paves Way for More Automated Liquid Biopsies
- New Tool Maps Chromosome Shifts in Cancer Cells to Predict Tumor Evolution
- Blood Test Identifies Inflammatory Breast Cancer Patients at Increased Risk of Brain Metastasis
- Newly-Identified Parkinson’s Biomarkers to Enable Early Diagnosis Via Blood Tests
- New Blood Test Could Detect Pancreatic Cancer at More Treatable Stage
- Liquid Biopsy Could Replace Surgical Biopsy for Diagnosing Primary Central Nervous Lymphoma
- New Tool Reveals Hidden Metabolic Weakness in Blood Cancers
- World's First Blood Test Distinguishes Between Benign and Cancerous Lung Nodules
- Rapid Test Uses Mobile Phone to Identify Severe Imported Malaria Within Minutes
- Gut Microbiome Signatures Predict Long-Term Outcomes in Acute Pancreatitis
- Blood Test Promises Faster Answers for Deadly Fungal Infections
- Blood Test Could Detect Infection Exposure History
- Urine-Based MRD Test Tracks Response to Bladder Cancer Surgery
Channels
Clinical Chemistry
view channel
New PSA-Based Prognostic Model Improves Prostate Cancer Risk Assessment
Prostate cancer is the second-leading cause of cancer death among American men, and about one in eight will be diagnosed in their lifetime. Screening relies on blood levels of prostate-specific antigen... Read more
Extracellular Vesicles Linked to Heart Failure Risk in CKD Patients
Chronic kidney disease (CKD) affects more than 1 in 7 Americans and is strongly associated with cardiovascular complications, which account for more than half of deaths among people with CKD.... Read moreHematology
view channel
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read more
Fast and Easy Test Could Revolutionize Blood Transfusions
Blood transfusions are a cornerstone of modern medicine, yet red blood cells can deteriorate quietly while sitting in cold storage for weeks. Although blood units have a fixed expiration date, cells from... Read more
Automated Hemostasis System Helps Labs of All Sizes Optimize Workflow
High-volume hemostasis sections must sustain rapid turnaround while managing reruns and reflex testing. Manual tube handling and preanalytical checks can strain staff time and increase opportunities for error.... Read more
High-Sensitivity Blood Test Improves Assessment of Clotting Risk in Heart Disease Patients
Blood clotting is essential for preventing bleeding, but even small imbalances can lead to serious conditions such as thrombosis or dangerous hemorrhage. In cardiovascular disease, clinicians often struggle... Read moreImmunology
view channelBlood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more
Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
Immunotherapy has transformed cancer treatment, but only a small proportion of patients experience lasting benefit, with response rates often remaining between 10% and 20%. Clinicians currently lack reliable... Read moreMicrobiology
view channel
Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease
Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read moreAI-Powered Platform Enables Rapid Detection of Drug-Resistant C. Auris Pathogens
Infections caused by the pathogenic yeast Candida auris pose a significant threat to hospitalized patients, particularly those with weakened immune systems or those who have invasive medical devices.... Read morePathology
view channel
Engineered Yeast Cells Enable Rapid Testing of Cancer Immunotherapy
Developing new cancer immunotherapies is a slow, costly, and high-risk process, particularly for CAR T cell treatments that must precisely recognize cancer-specific antigens. Small differences in tumor... Read more
First-Of-Its-Kind Test Identifies Autism Risk at Birth
Autism spectrum disorder is treatable, and extensive research shows that early intervention can significantly improve cognitive, social, and behavioral outcomes. Yet in the United States, the average age... Read moreTechnology
view channel
Robotic Technology Unveiled for Automated Diagnostic Blood Draws
Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more
ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals
Clinical laboratories generate billions of test results each year, creating a treasure trove of data with the potential to support more personalized testing, improve operational efficiency, and enhance patient care.... Read moreAptamer Biosensor Technology to Transform Virus Detection
Rapid and reliable virus detection is essential for controlling outbreaks, from seasonal influenza to global pandemics such as COVID-19. Conventional diagnostic methods, including cell culture, antigen... Read more
AI Models Could Predict Pre-Eclampsia and Anemia Earlier Using Routine Blood Tests
Pre-eclampsia and anemia are major contributors to maternal and child mortality worldwide, together accounting for more than half a million deaths each year and leaving millions with long-term health complications.... Read moreIndustry
view channelNew Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing
Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
AI-Powered Cervical Cancer Test Set for Major Rollout in Latin America
Noul Co., a Korean company specializing in AI-based blood and cancer diagnostics, announced it will supply its intelligence (AI)-based miLab CER cervical cancer diagnostic solution to Mexico under a multi‑year... Read more
Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform
Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more







